|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2001-3-6
|
|
pubmed:abstractText |
AC133 is a novel monoclonal antibody (Moab) reacting with a population of immature/primitive or granulo-monocytic committed CD34+ve cells. Up to now, only few studies with small numbers of cases have examined AC133 (recently designated CD133) expression in acute leukemia. To determine the value of this Moab for acute leukemia immunophenotyping, we investigated a large series of leukemic cell samples for their reactivity with Moab AC133. DESIGN AND METHODS. A total of 298 cell samples from patients with de novo acute myeloid leukemia (AML) (n=142), acute lymphoblastic leukemia (ALL) (n=119), CD34+ve biphenotypic acute leukemia (n=13), and CD34+ve CML blast crisis (=BC; 21 myeloid BC/3 lymphoid BC) were investigated by flow cytometry for Moab AC133 reactivity.CD133 expression was compared with CD90(Thy-1) expression, another CD34-associated antigen.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/AC133 antigen,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD34,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Thy-1,
http://linkedlifedata.com/resource/pubmed/chemical/Glycoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/Peptides
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0390-6078
|
|
pubmed:author |
pubmed-author:CreutzigUU,
pubmed-author:HaferlachTT,
pubmed-author:HarbottJJ,
pubmed-author:KarawajewLL,
pubmed-author:LudwigW DWD,
pubmed-author:RateiRR,
pubmed-author:SchnittgerSS,
pubmed-author:SchochCC,
pubmed-author:SperlingCC,
pubmed-author:TRCKAVV,
pubmed-author:WuchterCC
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
86
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
154-61
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11224484-Acute Disease,
pubmed-meshheading:11224484-Adolescent,
pubmed-meshheading:11224484-Adult,
pubmed-meshheading:11224484-Aged,
pubmed-meshheading:11224484-Aged, 80 and over,
pubmed-meshheading:11224484-Antibodies, Monoclonal,
pubmed-meshheading:11224484-Antigens, CD,
pubmed-meshheading:11224484-Antigens, CD34,
pubmed-meshheading:11224484-Antigens, Thy-1,
pubmed-meshheading:11224484-Cell Lineage,
pubmed-meshheading:11224484-Child,
pubmed-meshheading:11224484-Child, Preschool,
pubmed-meshheading:11224484-Glycoproteins,
pubmed-meshheading:11224484-Hematopoietic Stem Cells,
pubmed-meshheading:11224484-Humans,
pubmed-meshheading:11224484-Immunophenotyping,
pubmed-meshheading:11224484-Infant,
pubmed-meshheading:11224484-Leukemia,
pubmed-meshheading:11224484-Middle Aged,
pubmed-meshheading:11224484-Peptides
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Impact of CD133 (AC133) and CD90 expression analysis for acute leukemia immunophenotyping.
|
|
pubmed:affiliation |
Robert-Rössle-Clinic, Charité, Humboldt University of Berlin, Lindenberger Weg 80, 13125 Berlin, Germany. wuchter@rrk-berlin.de
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
